Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 6, 2022
Daily News
December 6, 2022
- Yukinari Kono Named as Chief of Baxter Japan
December 6, 2022
- Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
- Delete Contraindications on Use of Amlodipine, Nifedipine in Pregnant Women: MHLW
December 6, 2022
- 88% of Japanese Have Confidence in Pharma Industry: JPMA
December 6, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- PeptiDream, RayzeBio Pick 1st Peptide Radiopharmaceutical Candidate
December 6, 2022
- Keytruda Filed in Japan for Primary Mediastinal Large B-Cell Lymphoma
December 6, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…